Cavity frequency-dependent theory for vibrational polariton chemistry
Recent experiments show the management of chemical reactivities by coupling molecules inside an optical microcavity. In distinction, transition state theory predicts no change of the response barrier top throughout this course of. Here, we current a theoretical rationalization of the cavity modification of the bottom state reactivity within the vibrational robust coupling (VSC) regime in polariton chemistry. Our theoretical outcomes recommend that the VSC kinetics modification is originated from the non-Markovian dynamics of the cavity radiation mode that {couples} to the molecule, resulting in the dynamical caging impact of the response coordinate and the suppression of response charge fixed for a particular vary of photon frequency near the barrier frequency.
We use a easy analytical non-Markovian charge theory to explain a single molecular system coupled to a cavity mode. We show the accuracy of the speed theory by performing direct numerical calculations of the transmission coefficients with the identical mannequin of the molecule-cavity hybrid system. Our simulations and analytical theory present a believable rationalization of the photon frequency dependent modification of the chemical reactivities within the VSC polariton chemistry.
The impossibility of experiencing the molecular world with our senses hampers instructing and understanding chemistry as a result of very summary ideas (resembling atoms, chemical bonds, molecular construction, reactivity) are required for this course of. Virtual actuality, particularly when based mostly on express bodily modeling (probably in actual time), gives an answer to this dilemma. Chemistry instructing could make use of superior applied sciences resembling virtual-reality frameworks and haptic units.
We present how an immersive studying setting may very well be utilized to assist college students perceive the core ideas of typical chemical reactions by providing a way more intuitive method than conventional studying settings. Our setting depends on an interactive exploration and manipulation of a chemical system; this method is simulated in real-time with quantum chemical strategies, and subsequently, behaves in a bodily significant manner.
Simulation of the consequences of forest harvesting beneath altering local weather to tell long-term sustainable forest administration utilizing a biogeochemical mannequin
Process ecosystem fashions are helpful instruments to offer perception on advanced, dynamic ecological methods, and their response to disturbances. The biogeochemical mannequin PnET-BGC was modified and examined utilizing subject observations from an experimentally whole-tree harvested northern hardwood watershed (W5) on the Hubbard Brook Experimental Forest (HBEF), New Hampshire, USA. Modelling of the Cascadia and Kyushu subduction zones reveals that the merchandise of sediment melting carefully reproduce the magnetotelluric observations.
In this research, the confirmed mannequin was used as a heuristic device to analyze long-term adjustments in hydrology, biomass accumulation, and soil resolution and stream water chemistry for three completely different watershed slicing intensities and three rotation lengths beneath each fixed (present local weather) and altering future local weather situations and atmospheric CO2 via the yr 2200. For the no future slicing situation, complete ecosystem saved carbon (i.e., sum of aboveground biomass, woody particles and soil) reached a most worth of 207 t C ha-1 beneath fixed local weather however elevated to 452 t C ha-1 beneath altering local weather in 2200 as a consequence of a CO2 fertilization impact.
Harvesting of timber decreased complete ecosystem saved carbon between 7 and 36% for fixed local weather and 7-60% beneath altering local weather, respectively, with better reductions for shorter logging rotation lengths and better watershed slicing intensities. Harvesting beneath local weather change resulted in noticeable losses of soil natural matter (12-56%) coinciding with lack of soil vitamins primarily as a consequence of increased charges of soil mineralization related to will increase in temperature, in contrast with fixed local weather situations.
Cumulative stream leaching of nitrate beneath local weather change exceeded fixed local weather values for the varied slicing regimes. Under each local weather situations the mannequin projected better sensitivity to various the size of slicing interval than slicing intensities. Hypothetical mannequin simulations spotlight future challenges in sustaining long-term productiveness of managed forests beneath altering local weather as a consequence of a possible for a deterioration of soil fertility.
Melting of subducted sediments reconciles geophysical pictures of subduction zones
Sediments play a key function in subduction. They assist management the chemistry of arc volcanoes and the placement of seismic hazards. Here, we current a brand new mannequin describing the destiny of subducted sediments that explains magnetotelluric fashions of subduction zones, which generally present an enigmatic conductive anomaly on the trenchward aspect of volcanic arcs. In many subduction zones, sediments will soften trenchward of the supply area for arc melts. High-pressure experiments present that these sediment melts will react with the overlying mantle wedge to supply electrically conductive phlogopite pyroxenites.
Genorise® Recombinant Equine IFN alpha protein |
|||
GR104329 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant (HEK) Hemagglutinin Influenza A Virus H3N8 (A/equine/Gansu/7/2008) HA protein (1-344, His-tag, >95%) |
|||
RP-1625 | Alpha Diagnostics | 10 ug | EUR 416.4 |
Recombinant Equine IFN-γ |
|||
QEIFP-0101 | Cyagen | 100ug | Ask for price |
Recombinant Equine IL-1β |
|||
QEILP-0101 | Cyagen | 10ug | Ask for price |
Recombinant Equine IL-1RA |
|||
QEILP-0102 | Cyagen | 5ug | Ask for price |
Equine CCL3 Recombinant Protei |
|||
R00405-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Chemokine ligand 3 (CCL3), also known as Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha), is a small cytokine belonging to the CC chemokine family. CCL3 (MIP-1 alpha) is a chemoattractant for several different leukocytes, with varying degrees of potency. Equine CCL3 Recombinant Protein is purified chemokine ligand 3 (CCL3, MIP-1 alpha) produced in yeast. |
Equine EPO Recombinant Protein |
|||
R00484-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Erythropoietin (EPO) is an essential hormone for red blood cell production. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. Equine Erythropoietin Recombinant Protein is purified Erythropoietin (EPO) produced in yeast. |
Equine CCL5 Recombinant Protei |
|||
R00617-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: CCL5, also known as RANTES (regulated and normal T cell expressed and secreted), is a member of the C-C Chemokine Family. RANTES (CCL5) is chemotactic for T cells, eosinophils, and basophils, and plays an active role in recruiting leukocytes into inflammatory sites. Equine CCL5 Recombinant Protein is purified CCL5 (RANTES) produced in yeast. |
Equine CCL2 Recombinant Protein |
|||
R00056-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemotactic protein-1 (MCP-1), is a small cytokine belonging to the CC chemokine family. CCL2 (MCP-1) recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection. Equine CCL2 (MCP-1) Recombinant Protein is purified CCL2 (MCP-1) produced in yeast. |
Equine CXCL9 Recombinant Protein |
|||
R01397-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: CXCL9 (MIG) is a T-cell chemoattractant. Induced by IFN-gamma (IFN-γ), the ELR-negative chemokine CXCL9 (MIG) elicits its effects by binding to the cell surface chemokine receptor CXCR3. Equine CXCL9 Recombinant Protein is purified CXCL9 (MIG) produced in yeast. |
Equine CCL11 Recombinant Protein |
|||
R01438-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Chemokine ligand 11 (CCL11) belongs to the CC chemokine family and is commonly known as Eotaxin-1. CCL11 (Eotaxin-1) selectively recruits eosinophils by inducing their chemotaxis, and therefore, is implicated in allergic responses. Equine CCL11 Recombinant Protein is purified chemokine ligand 11 (CCL11, Eotaxin-1) produced in yeast. |
Recombinant Equine Interferon-gamma |
|||
AP60276 | SAB | 500ug | EUR 885 |
Equine CXCL10 Recombinant Protein |
|||
R00278-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: The ELR-negative CXC chemokine CXCL10 (IP-10) has been attributed to several roles, such as chemoattraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis. Equine CXCL10 Recombinant Protein is purified CXCL10 (IP-10) produced in yeast. |
Recombinant (E.Coli) Human p38 alpha/SAPK2 alpha |
|||
RP-675 | Alpha Diagnostics | 1 ug | EUR 343.2 |
Genorise® Recombinant Equine HGF |
|||
GR104207 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine BNP |
|||
GR104274 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR1 |
|||
GR104008 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR2 |
|||
GR104009 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR3 |
|||
GR104010 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR5 |
|||
GR104011 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR7 |
|||
GR104012 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TLR9 |
|||
GR104013 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine VEGF |
|||
GR104209 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine cTnT |
|||
GR104288 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine cTnI |
|||
GR104289 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant Equine IL-2 Cys141Ser |
|||
QEILP-0201 | Cyagen | 10ug | Ask for price |
Equine IL-13 Recombinant Protei |
|||
R00077-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IL-13 is an important mediator of allergic inflammation and disease. In addition to effects on immune cells, IL-13 is implicated as a central mediator of the physiologic changes induced by allergic inflammation in many tissues. Equine IL-13 Recombinant Protein is purified interleukin-13 produced in yeast. |
Equine IL-6 Recombinant Protein |
|||
R00102-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. Equine IL-6 Recombinant Protein is purified interleukin-6 produced in yeast. |
Equine IL-4 Recombinant Protein |
|||
R00230-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IL-4 has many biological roles, including the stimulation of activated B-cell and T-cell proliferation, and the differentiation of CD4+ T-cells into Th2 cells. It is a key regulator in humoral and adaptive immunity. Equine IL-4 Recombinant Protein is purified interleukin-4 produced in yeast. |
Equine IL-2 Recombinant Protein |
|||
R00387-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Interleukin-2 (IL-2) is a cytokine produced by T-helper cells in response to antigenic or mitogenic stimulation. It is required for T-cell proliferation and other activities crucial to the regulation of the immune response. Equine IL-2 Recombinant Protein is purified interleukin-2 produced in yeast. |
Equine IL-8 Recombinant Protein |
|||
R00423-5 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Interleukin-8 (IL-8), also known as CXCL8, is an ELR-positive CXC family member chemokine produced by macrophages and other cell types such as epithelial cells. ELR-positive CXC chemokines such as IL-8 specifically induce the migration of neutrophils, and interact with chemokine receptors CXCR1 and CXCR2. Equine IL-8 Recombinant Protein is purified interleukin-8 produced in yeast. |
Equine IL-5 Recombinant Protein |
|||
R01086-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: The IL-5 cytokine has a key role in regulating eosinophil development and is responsible for selective terminal differentiation of eosinophils. It is associated with the cause of several allergic diseases including allergic rhinitis and asthma. Equine IL-5 Recombinant Protein is purified interleukin-5 produced in yeast. |
Genorise® Recombinant Equine ProBNP |
|||
GR104275 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine SLC2A1 |
|||
GR104287 | Genorise Scientific | 5 µg | EUR 285 |
Equine IL-10 Recombinant Protein |
|||
R00021-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IL-10 is an anti-inflammatory cytokine and a member of the IL-10 family of cytokines, which have indispensable functions in many infectious and inflammatory diseases. Equine IL-10 Recombinant Protein is purified interleukin-10 produced in yeast. |
Equine IL-15 Recombinant Protein |
|||
R00212-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Equine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast. |
Recombinant Equine Interleukin-1 beta |
|||
AP60273 | SAB | 100ug | EUR 1398 |
Equine VEGF-A Recombinant Protein |
|||
R00045-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Equine VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast. |
Equine IL-17A Recombinant Protein |
|||
R00421-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IL-17A is a member of the IL-17 family of cytokines, whose members are involved in numerous immune regulatory functions. IL-17 induces the production of many other cytokines, chemokines, and prostaglandins. Equine IL-17A Recombinant Protein is purified interleukin-17A produced in yeast. |
Equine IL-1ra Recombinant Protein |
|||
R00651-4 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Interleukin-1 Receptor Antagonist Protein (IL-1F3, IL-1ra) belongs to the IL-1 family of cytokines, whose members play key roles in the development and regulation of inflammation. IL-1 receptor antagonist (IL-1ra; IL-1F3) reduces inflammation by blocking the binding of the agonist receptor ligands. Equine IL-1 Receptor Antagonist Recombinant Protein is purified interleukin-1 receptor antagonist protein (IL-1F3, IL-1ra) produced in yeast. |
Equine GM-CSF Recombinant Protein |
|||
R00911-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Equine GM-CSF Recombinant Protein is purified GM-CSF produced in yeast |
Genorise® Recombinant equine IL-2 |
|||
GR104002 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-5 |
|||
GR104003 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-6 |
|||
GR104004 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-4 |
|||
GR104151 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IL-8 |
|||
GR104210 | Genorise Scientific | 5 µg | EUR 285 |
Equine IFN gamma Recombinant Protein |
|||
R00393-5 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IFN-gamma, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Equine IFN gamma Recombinant Protein is purified IFN gamma produced in yeast. |
Genorise® Recombinant equine IL-1β |
|||
GR104001 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-10 |
|||
GR104005 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-12 |
|||
GR104006 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine IL-15 |
|||
GR104007 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-1 |
|||
GR104017 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-2 |
|||
GR104018 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-3 |
|||
GR104019 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-4 |
|||
GR104020 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-4 |
|||
GR104020-50 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-5 |
|||
GR104021 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-6 |
|||
GR104022 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-7 |
|||
GR104023 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IL-13 |
|||
GR104211 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine sTNF RI |
|||
GR104214 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine BMP-8a |
|||
GR104024 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IL-1RA |
|||
GR104170 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine sIL-2R |
|||
GR104212 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine sIL-6R |
|||
GR104213 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine sTNF RII |
|||
GR104220 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine H-FABP |
|||
GR104286 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine GM-CSF |
|||
GR104290 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant Human Alpha-Synuclein |
|||
RP-847 | Alpha Diagnostics | 20 ug | EUR 196.8 |
Genorise® Recombinant Equine Osteopontin |
|||
GR104273 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine PDGF-AA |
|||
GR104208 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine PDGF-BB |
|||
GR104254 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant Equine Interleukin-2 Cys141Ser |
|||
AP60275 | SAB | 100ug | EUR 1398 |
Genorise® Recombinant equine IFN-gamma |
|||
GR104150 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine LIF protein |
|||
GR104298 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine KGF protein |
|||
GR104307 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine MSP protein |
|||
GR104308 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine NGF protein |
|||
GR104317 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine EGF protein |
|||
GR104324 | Genorise Scientific | 5 µg | EUR 285 |
Equine IL-1 beta Recombinant Protein |
|||
R00101-3 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IL-1 beta (IL-1β) is a member of the interleukin 1 family of cytokines. The IL-1 beta cytokine is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE). This cytokine is an important mediator of the inflammatory response, and is involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. Equine IL-1 beta Recombinant Protein is purified interleukin-1 beta cytokine produced in yeast. |
Equine IL-12 p40 Recombinant Protein |
|||
R01152-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: The IL-12 p40 subunit, or interleukin-12 beta subunit, is the 40 kD cytokine receptor-like subunit of the heterodimeric cytokines IL-12 and IL-23. IL-12 is involved in the differentiation of naive T cells into Th1 cells and the growth and function of T cells. Both IL-23 and IL-12 can activate the transcription activator STAT4 and stimulate the production of interferon-gamma (IFNG). Equine IL-12 p40 Recombinant Protein is purified interleukin-12 p40 produced in yeast. |
Equine IFN beta 1 Recombinant Protein |
|||
R02041-1 | BosterBio | 5ug/vial | EUR 310.8 |
Description: IFN beta is a mammalian Type I inferferon, functionig as a regulator of cellular activity by interacting with cell-surface receptors and activating various signaling pathways. IFN beta produces antiviral, antibacterial, and anticancer properties. Equine IFN beta Recombinant Protein is purified IFN beta produced in yeast. |
Genorise® Recombinant Equine BDNF protein |
|||
GR104293 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine CNTF protein |
|||
GR104297 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine GDNF protein |
|||
GR104302 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine GDF9 protein |
|||
GR104306 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine PIGF protein |
|||
GR104310 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Leptin protein |
|||
GR104292 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Artemin protein |
|||
GR104305 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant (E.Coli) Human Thyrostimulin Alpha |
|||
RP-595 | Alpha Diagnostics | 10 ug | EUR 343.2 |
Genorise® Recombinant equine TGF-beta 1 |
|||
GR104014 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TGF-beta 2 |
|||
GR104015 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant equine TGF-beta 3 |
|||
GR104016 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant purified, human Interleukin-1 alpha (IL-1 alpha), active |
|||
IL1A15-R-10 | Alpha Diagnostics | 10 ug | EUR 416.4 |
Recombinant (E.Coli) Human Crystallin Alpha A |
|||
RP-611 | Alpha Diagnostics | 20 ug | EUR 196.8 |
Recombinant (E.Coli) Human Crystallin Alpha B |
|||
RP-612 | Alpha Diagnostics | 20 ug | EUR 196.8 |
Genorise® Recombinant Equine Neurturin protein |
|||
GR104303 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Persephin protein |
|||
GR104304 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IGF-1 protein |
|||
GR104294 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IGF-2 protein |
|||
GR104295 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine TGF-α protein |
|||
GR104296 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine M-CSF protein |
|||
GR104299 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine G-CSF protein |
|||
GR104300 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine GDF-8 protein |
|||
GR104309 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IL-19 protein |
|||
GR104327 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant (E.Coli) purified human Tumor Necrosis Factor-Alpha (TNF-alpha), biologically active |
|||
TNFA15-R-10 | Alpha Diagnostics | 10 ug | EUR 270 |
Recombinant (E.Coli) purified rat Tumor Necrosis Factor-Alpha (TNF-alpha), biologically active |
|||
TNFA25-R-5 | Alpha Diagnostics | 5 ug | EUR 270 |
Recombinant (E.Coli) purified mouse Tumor Necrosis Factor-Alpha (TNF-alpha), biologically active |
|||
TNFA35-R-5 | Alpha Diagnostics | 5 ug | EUR 270 |
Genorise® Recombinant Equine GM-CSF protein |
|||
GR104301 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IFN beta protein |
|||
GR104328 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine GDF-15 protein |
|||
GR104330 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine IL-17C protein |
|||
GR104331 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant (E.Coli) Human Estrogen Receptor Alpha |
|||
RP-940 | Alpha Diagnostics | 2 ug | EUR 416.4 |
Genorise® Recombinant Equine Ephrin A1 protein |
|||
GR104320 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Ephrin A2 protein |
|||
GR104321 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Ephrin B1 protein |
|||
GR104322 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Ephrin B2 protein |
|||
GR104323 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine FGF Basic protein |
|||
GR104325 | Genorise Scientific | 5 µg | EUR 285 |
Human Alpha Synuclein (A30P) Recombinant protein |
|||
SYN-A30P-R | Alpha Diagnostics | 50ug | EUR 315.6 |
Human Alpha Synuclein (A53T) Recombinant protein |
|||
SYN-A53T-R | Alpha Diagnostics | 50ug | EUR 315.6 |
Recombinant (E.Coli) purified porcine Tumor Necrosis Factor-Alpha (TNF-alpha), biologically active |
|||
TNFA36-R-5 | Alpha Diagnostics | 5 ug | EUR 270 |
Recombinant (E.Coli) Human Casein Kinase 2 alpha |
|||
RP-666 | Alpha Diagnostics | 3 ug | EUR 708 |
Recombinant (Sf9) Human Protein Kinase C alpha |
|||
RP-676 | Alpha Diagnostics | 10 ug | EUR 343.2 |
Genorise® Recombinant Equine FGF Acidic protein |
|||
GR104326 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant Rat TNF alpha |
|||
EPT089 | ELK Biotech | 50ug | EUR 353.4 |
Description: Recombinant Rat Tumor Necrosis Factor is produced by our E.coli expression system and the target gene encoding Leu80-Leu235 is expressed. |
Genorise® Recombinant Equine Thrombopoietin protein |
|||
GR104311 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant (E.Coli) Human Retinoid X Receptor Alpha |
|||
RP-1588 | Alpha Diagnostics | 10 ug | EUR 270 |
Recombinant Mouse TNF alpha |
|||
6498 | Immunochemistry | 5 µg | EUR 194 |
Recombinant Human TNF alpha |
|||
6526 | Immunochemistry | 5 µg | EUR 194 |
Recombinant Human TNF alpha |
|||
EPT038 | ELK Biotech | 50ug | EUR 137.4 |
Description: Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Val77-Leu233 is expressed. |
Recombinant Mouse TNF alpha |
|||
EPT045 | ELK Biotech | 10ug | EUR 119.4 |
Description: Recombinant Mouse Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Asp89-Leu235 is expressed. |
Recombinant (E.Coli) Zea Mays Casein Kinase 2 alpha |
|||
RP-668 | Alpha Diagnostics | 3 ug | EUR 708 |
Recombinant Equine infectious anemia p26 Antigen-1 |
|||
E41H034 | EnoGene | 100ug | EUR 695 |
Recombinant Equine infectious anemia p26 Antigen-2 |
|||
E41H035 | EnoGene | 100ug | EUR 695 |
Bovine TNF alpha Recombinant |
|||
R00002-2 | BosterBio | 5ug/vial | EUR 310.8 |
Description: Tumor necrosis factor alpha (TNFSF2, TNF alpha) is a member of the TNF Superfamily. TNF alpha, being an endogenous pyrogen, is able to induce fever, to induce apoptotic cell death, to induce sepsis (through IL-1 & IL-6 production), to induce cachexia, induce inflammation, and to inhibit tumorigenesis and viral replication. Bovine TNF alpha Recombinant Protein is purified TNF alpha (TNFSF2) produced in yeast. |
Recombinant (P. Pastoris) Human collagen alpha-III |
|||
RP-920 | Alpha Diagnostics | 10 mg | EUR 634.8 |
Genorise® Recombinant Equine Angiostatin 1 protein |
|||
GR104312 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Angiostatin 2 protein |
|||
GR104313 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Angiostatin 3 protein |
|||
GR104314 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Angiostatin 4 protein |
|||
GR104315 | Genorise Scientific | 5 µg | EUR 285 |
Genorise® Recombinant Equine Angiostatin 5 protein |
|||
GR104316 | Genorise Scientific | 5 µg | EUR 285 |
Recombinant Equine Leptin Protein, Untagged, E.coli-1mg |
|||
QP10753-1mg | EnQuireBio | 1mg | EUR 1220.4 |
Recombinant (E.Coli) Human Protein Phosphatase 2C alpha |
|||
RP-680 | Alpha Diagnostics | 10 ug | EUR 270 |
TNF alpha Recombinant Protein |
|||
40-446-0005mg | ProSci | 0.005 mg | EUR 311.1 |
Description: TNF-alpha is a pleiotrophic pro-inflammatory cytokine secreted by various cells including adipocytes, activated monocytes, macrophages, B cells, T cells and fibroblasts. It belongs to the TNF family of ligands and signals through two receptors, TNFR1 and TNFR2. TNF-alpha is cytotoxic to a wide variety of tumor cells and is an essential factor in mediating the immune response against bacterial infections. TNF-alpha also plays a role in the induction of septic shock, auto immune diseases, rheumatoid arthritis, inflammation, and diabetes. Recombinant murine TNF-alpha is a soluble 156 amino acid protein (17.3 kDa) which corresponds to C-terminal extracellular domain of the full length transmembrane protein. |
TNF alpha Recombinant Protein |
|||
40-446-002mg | ProSci | 0.02 mg | EUR 437.1 |
Description: TNF-alpha is a pleiotrophic pro-inflammatory cytokine secreted by various cells including adipocytes, activated monocytes, macrophages, B cells, T cells and fibroblasts. It belongs to the TNF family of ligands and signals through two receptors, TNFR1 and TNFR2. TNF-alpha is cytotoxic to a wide variety of tumor cells and is an essential factor in mediating the immune response against bacterial infections. TNF-alpha also plays a role in the induction of septic shock, auto immune diseases, rheumatoid arthritis, inflammation, and diabetes. Recombinant murine TNF-alpha is a soluble 156 amino acid protein (17.3 kDa) which corresponds to C-terminal extracellular domain of the full length transmembrane protein. |
TNF alpha Recombinant Protein |
|||
40-468-0005mg | ProSci | 0.005 mg | EUR 311.1 |
Description: TNF-β is a pleiotrophic pro-inflammatory cytokine secreted by various cells including adipocytes, activated monocytes, macrophages, B cells, T cells and fibroblasts. It belongs to the TNF family of ligands and signals through two receptors, TNFR1 and TNFR2. TNF-β is cytotoxic to a wide variety of tumor cells and is an essential factor in mediating the immune response against bacterial infections. TNF-β also plays a role in the induction of septic shock, auto immune diseases, rheumatoid arthritis, inflammation, and diabetes. Recombinant rat TNF-β is a soluble 157 amino acid protein (17.3 kDa) which corresponds to C-terminal extracellular domain of the full length transmembrane protein. |
TNF alpha Recombinant Protein |
|||
40-468-002mg | ProSci | 0.02 mg | EUR 437.1 |
Description: TNF-β is a pleiotrophic pro-inflammatory cytokine secreted by various cells including adipocytes, activated monocytes, macrophages, B cells, T cells and fibroblasts. It belongs to the TNF family of ligands and signals through two receptors, TNFR1 and TNFR2. TNF-β is cytotoxic to a wide variety of tumor cells and is an essential factor in mediating the immune response against bacterial infections. TNF-β also plays a role in the induction of septic shock, auto immune diseases, rheumatoid arthritis, inflammation, and diabetes. Recombinant rat TNF-β is a soluble 157 amino acid protein (17.3 kDa) which corresponds to C-terminal extracellular domain of the full length transmembrane protein. |
TNF alpha Recombinant Protein |
|||
91-006 | ProSci | 0.05 mg | EUR 405.6 |
Description: TNF alpha is a homotrimer with a subunit molecular mass of 17 kD and plays a major role in growth regulation, differentiation, inflammation, viral replication, tumorigenesis, autoimmune diseases and in viral, bacterial, fungal, and parasitic infections. Besides inducing hemorrhagic necrosis of tumors, TNF was found to be involved in tumorigenesis, tumor metastasis, viral replication, septic shock, fever, inflammation, and autoimmune diseases including Crohn’s disease, and rheumatoid arthritis as well as graft-versus-host disease. |
TNF alpha Recombinant Protein |
|||
91-027 | ProSci | 0.05 mg | EUR 619.8 |
Description: Tumor Necrosis Factor- alpha (TNF- alpha) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- alpha while cells that express CD8 secrete little or no TNF- alpha. Synthesis of TNF- alpha can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF- alpha has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF- alpha mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- alpha that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF- alpha, which binds to both murine TNF receptors. Based on these results, many TNF- alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- alpha High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo. |
TNF alpha Recombinant Protein |
|||
91-068 | ProSci | 0.05 mg | EUR 714.3 |
Description: Tumor necrosis factor alpha (TNF alpha) is the prototypic ligand of the TNF superfamily. TNF alpha forms a homotrimer and functions by activating two types of receptors TNF-R1 (TNF receptor type 1,p55R) and TNF-R2 (TNF receptor type 2,p75R). TNF alpha is a pleiotropic cytokine that is capable to promote inflammation, to induce apoptotic cell death, and to inhibit tumorigenesis and viral replication. TNF alpha is a potent lymphoid factor that exerts cytotoxic effects on a wide range of tumor cells and certain other target cells. |
TNF alpha Recombinant Protein |
|||
92-067 | ProSci | 0.05 mg | EUR 651.3 |
Description: Tumor Necrosis Factor (TNF) is a member of the Tumor Necrosis Factor family. TNF exists as a homotrimer and interacts with SPPL2B. TNF is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. TNF is a key cytokine in the development of several inflammatory disorders. It contributes to the development of type 2 diabetes throught its effects on insulin resistance and fatty acid metabolism. |
TNF alpha Recombinant Protein |
|||
92-216 | ProSci | 0.05 mg | EUR 374.1 |
Description: Tumor Necrosis Factor- alpha (TNF- alpha) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- alpha while cells that express CD8 secrete little or no TNF- alpha. Synthesis of TNF- alpha can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF- alpha has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF- alpha mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- alpha that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF- alpha, which binds to both murine TNF receptors. Based on these results, many TNF- alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- alpha High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo. |
TNF alpha Recombinant Protein |
|||
92-217 | ProSci | 0.05 mg | EUR 821.4 |
Description: Tumor Necrosis Factor- alpha (TNF- alpha) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- alpha while cells that express CD8 secrete little or no TNF- alpha. Synthesis of TNF- alpha can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF- alpha has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF- alpha mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- alpha that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF- alpha, which binds to both murine TNF receptors. Based on these results, many TNF- alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- alpha High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo. |
IL-2 Interleukin-2 Equine Recombinant Protein |
|||
PROTP37997 | BosterBio | Regular: 20ug | EUR 380.4 |
Description: Recombinant Equine Interleukin-2 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 129 amino acids (with a substitution of S for C - at position 141 compared with the wild type IL2) and having a molecular mass of 14.9kDa.;The IL-2 Equine is purified by proprietary chromatographic techniques. |
Recombinant Equine IL 2 Protein, Untagged, E.coli-1mg |
|||
QP10700-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Recombinant Equine IL 2 Protein, Untagged, E.coli-5ug |
|||
QP10700-5ug | EnQuireBio | 5ug | EUR 186 |
Recombinant Equine Leptin Protein, Untagged, E.coli-20ug |
|||
QP10753-20ug | EnQuireBio | 20ug | EUR 186 |
Recombinant Equine IFN g Protein, Untagged, E.coli-1mg |
|||
QP10675-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Melting of subducted sediments may clarify Ok-rich volcanic rocks which might be produced when the phlogopite pyroxenites soften throughout slab roll-back occasions. This course of can also assist constrain fashions for subduction zone seismicity. Since melts and phlogopite each have low frictional power, damaging thrust earthquakes are unlikely to happen within the neighborhood of the melting sediments, whereas elevated fluid pressures might promote the prevalence of small magnitude earthquakes and episodic tremor and slip.